BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 22009993)

  • 1. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Poon H; Chang MH; Fung HB
    Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Lodise TP; Low DE
    Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline for complicated skin and skin-structure infections.
    Nannini EC; Stryjewski ME; Corey GR
    Expert Opin Pharmacother; 2010 May; 11(7):1197-206. PubMed ID: 20402556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
    Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
    File TM; Wilcox MH; Stein GE
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
    Garrison MW; Kawamura NM; Wen MM
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
    Casapao AM; Steed ME; Levine DP; Rybak MJ
    Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
    Med Lett Drugs Ther; 2011 Jan; 53(1356):5-6. PubMed ID: 21252841
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
    Steed ME; Rybak MJ
    Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection.
    Parish D; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Feb; 9(2):201-9. PubMed ID: 18246523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.
    Stryjewski ME; Jones RN; Corey GR
    Diagn Microbiol Infect Dis; 2015 Mar; 81(3):183-8. PubMed ID: 25583130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
    Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
    Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.